Evolving role of chemoradiation in the adjuvant treatment of gastric cancer

Expert Review of Anticancer Therapy

Volumn 4, Issue 4, 2004, Pages 585-594

  Leong, Trevor ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

Adjuvant therapy; Chemoradiation; Gastric cancer; Irinotecan; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LOMUSTINE; MITOMYCIN; PACLITAXEL; TAXANE DERIVATIVE;

AGRANULOCYTOSIS; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FEBRILE NEUTROPENIA; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HIGH RISK PATIENT; HUMAN; LEUKOPENIA; LYMPH NODE DISSECTION; NAUSEA; PREOPERATIVE CARE; REVIEW; STOMACH ADENOCARCINOMA;

EID: 4444243687     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.4.585     Document Type: Review

References (63)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J. Clin. 51, 15-36 (2001).
2. Neugut AI, Hayek M, Howe G. Epidemiology of gastric cancer. Semin. Oncol. 23, 281-291 (1996).
3. International Agency for Research on Cancer. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0. IARC Press, Lyon, France, IARC Cancer Base No. 5 (2001).
4. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 83, 2049-2053 (1998).
5. Hundahl SA, Menck HR, Mansour EG, Winchester DP. The National Cancer Database report on gastric carcinoma. Cancer 80, 2333-2341 (1997).
6. Wanebo HJ, Kennedy BJ, Chmiel J, Steele G, Winchester D, Osteen R. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann. Surg. 218, 583-592 (1993).
7. Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F, Sullinger J. Patterns of failure following curative resection of gastric carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 19, 1357-1362 (1990).
8. Caudry M, Escarmant P, Maire JP, Demeaux H, Guichard F, Azaloux H. Radiotherapy of gastric cancer with a three field combination: feasibility, tolerance and survival. Int. J. Radiat. Oncol. Biol. Phys. 13, 1821-1827 (1987).
9. Cuschieri A, Weeden S, Fielding J et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br. J. Cancer 79, 1522-1530 (1999).
10. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric cancer. Dutch Gastric Cancer Group. N. Engl. J. Med. 340, 908-914 (1999).
11. Kajitani T. The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J. Surg. 11, 127-139 (1981).
12. Mine M, Majima S, Harada M, Etani S. End results of gastrectomy for gastric cancer: effect of extensive lymph node dissection. Surgery 68, 753-758 (1970).
13. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J. Surg. 11, 418-425 (1987).
14. Nakajima T, Nishi M. Surgery and adjuvant chemotherapy for gastric cancer. Hepatogastroenterology 36, 79-85 (1989).
15. Pacelli F, Doglietto GB, Bellantone R, Alfieri S, Sgadari A, Crucitti F. Extensive versus limited lymph node dissection for gastric cancer: a comparative study of 320 patients. Br. J. Surg. 80, 1153-1156 (1993).
16. Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. Cancer 72, 2089-2097 (1993).
17. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch. Surg. 126, 1469-1473 (1991).
18. Cuschieri A, Fayers P, Fielding J et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Co-operative Group. Lancet 347, 995-999 (1996).
19. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br. J. Surg. 75, 110-112 (1988).
20. Robertson CS, Chung SC, Woods SD et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann. Surg. 220, 176-182 (1994).
21. Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br. J. Surg. 84, 567-571 (1997).
22. Hermans J, Bonenkamp JJ, Boon MC et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J. Clin. Oncol. 11, 1441-1447 (1993).
23. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials. Eur. J. Cancer 35, 1059-1064 (1999).
24. Mari F, Floriani I, Tinazzi A et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann. Oncol. 11, 837-843 (2000).
25. Janunger KG, Hafstrom L, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 40, 309-326 (2001).
26. Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Co-operative Group 82b Trial. N. Engl. J. Med. 337, 949-955 (1997).
27. Ragaz J, Jackson SM, Le N et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337, 956-962 (1997).
28. Camma C, Giunta M, Fiorica F, Pagliaro L, Craxi A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: a meta-analysis. JAMA 284, 1008-1015 (2000).
29. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys. 8, 1-11 (1982).
30. McNeer G, Vandenberg H Jr, Donn FY, Bowden L. A critical evaluation of subtotal gastrectomy for the cure of cancer of the stomach. Ann. Surg. 134, 2-7 (1951).
31. Thomson FB, Robins RE. Local recurrence following subtotal resection for gastric carcinoma. Surg. Gynecol. Obstet. 95, 341-344 (1952).
32. Hallissey MT, Dunn JA, Ward LC, Allum WH. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 343, 1309-1312 (1994).
33. Moertel CG, Childs DS, Reitemeier RJ, Colby MY, Holbrook MA. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2, 865-867 (1969).
34. Gastrointestinal Tumor Study Group. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer 49, 1771-1777 (1982).
35. Moertel CG, Childs DS, O'Fallon JR, Holbrook MA, Schutt AJ, Reitemeier RJ. Combined 5-fluorouracil and radiation therapy as a surgical adjuvant for poor prognosis gastric carcinoma. J. Clin. Oncol. 2, 1249-1254 (1984).
36. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 345, 725-730 (2001).
37. Smalley SR, Gunderson L, Tepper J et al. Gastric surgical adjuvant radiotherapy consensus report: rationale and treatment implementation. Int. J. Radiat. Oncol. Biol. Phys. 52, 283-293 (2002).
38. Dobelbower RR, Borgelt BB, Strubler KA, Kutcher GJ, Suntharalingam N. Precision radiotherapy for cancer of the pancreas: technique and results. Int. J. Radiat. Oncol. Biol. Phys. 6, 1127-1133 (1980).
39. Chu JC, Solin LJ, Hwang CC, Kessler H, Hanks GE. Three-dimensional dosimetric comparison of radiation therapy treatment planning of the pancreas. Med. Dosim. 17, 199-203 (1992).
40. Kapiteijn E, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N. Engl. J. Med. 345, 638-646 (2001).
41. Glimelius B. Has progress been made in gastrointestinal cancer treatment? Acta Oncol. 41, 115-117 (2002).
42. Leong T, Michael M, Foo K et al. Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. Br. J. Cancer 89, 1433-1438 (2003).
43. Findlay M, Cunningham D, Norman A et al. A Phase II study in advanced gastroesophageal. cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann. Oncol. 5, 609-616 (1994).
44. Waters JS, Norman A, Cunningham D et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br. J. Cancer 80, 269-272 (1999).
45. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MRC MAGIC trial, ISRCTN 93793971). Proc. Am. Soc. Clin. Oncol. 22, 249 (2003).
46. Boku N, Ohtsu A, Shimada Y et al. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J. Clin. Oncol. 17, 319-323 (1999).
47. Ajani JA, Baker J, Pisters PW et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a Phase II study. Cancer 94, 641-646 (2002).
48. Shirao K, Shimada Y, Kondo H et al. Phase I/II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer. J. Clin. Oncol. 15, 921-927 (1997).
49. Bugat R. Irinotecan in the treatment of gastric cancer. Ann. Oncol. 14(Suppl. 2), 37-40 (2003).
50. Komaki R, Janjan NA, Ajani JA et al. Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors. Oncology 14, 34-37 (2000).
51. Kim YH, Shin SW, Kim BS et al. Paclitaxel, 5-fluorouracil and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma. Cancer 85, 295-301 (1999).
52. Roth AD, Maibach I, Martinelli G et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK) and the European Institute of Oncology (EIO). Ann. Oncol. 11, 301-306 (2000).
53. Roth AD, Ajani J. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol. 14(Suppl. 2), 41-44 (2003).
54. Di Cosimo S, Ferretti G, Fazio N et al. Docetaxel in advanced gastric cancer - review of the main clinical trials. Acta Oncol. 42, 693-700 (2003).
55. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer 5(Suppl. 1), 31-34 (2002).
56. Safran H, Wanebo HJ, Hesketh PJ et al. Paclitaxel and concurrent radiation for gastric cancer. Int. J. Radiat. Oncol. Biol. Phys. 46, 889-894 (2000).
57. Ajani JA, Van Cutsem E, Moiseyenko V et al. Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): interim results of a randomized Phase III trial (V325). Proc. Am. Soc. Clin. Oncol. 22, 249 (2003).
58. Roth AD, Maibach S, Falk S et al. Docetaxel/cisplatin/5FU (TCF) versus docetaxel/cisplatin (TC) versus epirubicin/cisplatin/5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): a randomized Phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). Proc. Am. Soc. Clin. Oncol. 23, 317 (2004).
59. Klinkenbijl JH, Jeekel J, Sahmoud T et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Co-operative Group. Ann Surg. 230, 776-782 (1999).
60. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann. Surg. 229, 303-308 (1999).
61. Lowy AM, Feig BW, Janjan N et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann. Surg. Oncol. 8, 519-524 (2001).
62. Zhang ZX, Gu XZ, Yin WB, Huang GJ, Zhang DW, Zhang RG. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC) - report on 370 patients. Int. J. Radiat. Oncol. Biol. Phys. 42, 929-934 (1998).
63. Skoropad VY, Berdov BA, Mardynski YS, Titova LN. A prospective, randomized trial of preoperative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur. J. Surg. Oncol. 26, 773-779 (2000).